Research programme: cachexia therapy - PhytoMedical Technologies

Drug Profile

Research programme: cachexia therapy - PhytoMedical Technologies

Alternative Names: BDC-03

Latest Information Update: 20 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PhytoMedical Technologies
  • Developer EMD Millipore; Ricerca Biosciences
  • Class Obesity therapies; Phytotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cachexia

Most Recent Events

  • 26 Aug 2011 No development reported - Preclinical for Cachexia in Canada (PO)
  • 26 Aug 2011 No development reported - Preclinical for Cachexia in USA (PO)
  • 12 Jul 2006 Ricerca BioSciences has entered into an agreement with PhytoMedical Technologies to develop BDC 03 for cachexia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top